• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用卡那单抗治疗全身型幼年特发性关节炎。

Treatment of systemic-onset juvenile arthritis with canakinumab.

作者信息

Peitz Joachim, Horneff Gerd

机构信息

Pediatric Rheumatology Centre, Department of General Pediatrics and Neonatology, Asklepios Clinic, Sankt Augustin, Germany.

出版信息

Open Access Rheumatol. 2015 Feb 18;7:23-31. doi: 10.2147/OARRR.S54215. eCollection 2015.

DOI:10.2147/OARRR.S54215
PMID:27790042
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5045123/
Abstract

Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoclonal human antibody for the treatment of systemic-onset juvenile idiopathic arthritis and describe its efficacy and safety. Canakinumab is an important, safe, and valid drug in the treatment of systemic-onset juvenile idiopathic arthritis.

摘要

全身型幼年特发性关节炎的治疗颇具挑战性，但针对白细胞介素-1和白细胞介素-6的细胞因子拮抗剂的出现显著拓展了治疗选择。在本综述中，我们重点关注了卡那单抗（一种用于治疗全身型幼年特发性关节炎的白细胞介素-1单克隆人源抗体）的当前应用经验，并描述了其疗效和安全性。卡那单抗是治疗全身型幼年特发性关节炎的一种重要、安全且有效的药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d55a/5045123/d8f9c527e292/oarrr-7-023Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d55a/5045123/659fd1d79a96/oarrr-7-023Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d55a/5045123/2e9e54601419/oarrr-7-023Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d55a/5045123/e7367b141200/oarrr-7-023Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d55a/5045123/8bd38667db57/oarrr-7-023Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d55a/5045123/d8f9c527e292/oarrr-7-023Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d55a/5045123/659fd1d79a96/oarrr-7-023Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d55a/5045123/2e9e54601419/oarrr-7-023Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d55a/5045123/e7367b141200/oarrr-7-023Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d55a/5045123/8bd38667db57/oarrr-7-023Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d55a/5045123/d8f9c527e292/oarrr-7-023Fig5.jpg

相似文献

1
Treatment of systemic-onset juvenile arthritis with canakinumab.用卡那单抗治疗全身型幼年特发性关节炎。
Open Access Rheumatol. 2015 Feb 18;7:23-31. doi: 10.2147/OARRR.S54215. eCollection 2015.
2
Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.卡那单抗用于治疗活动性全身型幼年特发性关节炎。
Expert Rev Clin Pharmacol. 2016 Aug;9(8):1015-24. doi: 10.1080/17512433.2016.1204910. Epub 2016 Jul 6.
3
Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).系统性幼年特发性关节炎初始治疗四种共识治疗方案的贝叶斯比较有效性研究：系统性幼年特发性关节炎治疗的一线选择（FROST）
Clin Trials. 2018 Jun;15(3):268-277. doi: 10.1177/1740774518761367. Epub 2018 Mar 15.
4
Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience.卡那单抗治疗全身型幼年特发性关节炎的疗效和安全性：中国首项临床经验
Pediatr Rheumatol Online J. 2024 Mar 19;22(1):38. doi: 10.1186/s12969-024-00974-4.
5
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.BIKER 登记研究中依那西普、托珠单抗和白细胞介素-1 抑制剂治疗全身型幼年特发性关节炎患者的经验。
Arthritis Res Ther. 2017 Nov 22;19(1):256. doi: 10.1186/s13075-017-1462-2.
6
Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis.使用标准剂量及增加剂量的卡那单抗来缓解全身型幼年特发性关节炎患儿的巨噬细胞活化综合征。
Front Pediatr. 2022 Jul 28;10:894846. doi: 10.3389/fped.2022.894846. eCollection 2022.
7
Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.靶向白细胞介素-1 的生物制剂治疗免疫介导性疾病的安全性和疗效的系统评价。
Front Immunol. 2022 Jul 6;13:888392. doi: 10.3389/fimmu.2022.888392. eCollection 2022.
8
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis.白细胞介素-1在全身型幼年特发性关节炎中的抑制作用
Front Pharmacol. 2016 Dec 6;7:467. doi: 10.3389/fphar.2016.00467. eCollection 2016.
9
Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.生物制剂治疗全身型幼年特发性关节炎的长期随访：来自德国 BIKER 注册研究的数据。
Rheumatology (Oxford). 2020 Sep 1;59(9):2287-2298. doi: 10.1093/rheumatology/kez577.
10
Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World Settings.美国真实世界环境中，系统性幼年特发性关节炎和成人斯蒂尔病患者开始使用卡那单抗的原因。
Rheumatol Ther. 2022 Feb;9(1):265-283. doi: 10.1007/s40744-021-00402-z. Epub 2021 Dec 7.

引用本文的文献

1
Beyond Diagnosis: Preliminary Study of Impact on Children and Parents in Neurodevelopmental Disorders and Juvenile Idiopathic Arthritis-Associated Uveitis.超越诊断：对神经发育障碍和青少年特发性关节炎相关性葡萄膜炎患儿及家长影响的初步研究
Diagnostics (Basel). 2024 Jan 26;14(3):275. doi: 10.3390/diagnostics14030275.
2
Research progress in drug therapy of juvenile idiopathic arthritis.幼年特发性关节炎的药物治疗研究进展。
World J Pediatr. 2022 Jun;18(6):383-397. doi: 10.1007/s12519-022-00530-8. Epub 2022 Apr 1.

本文引用的文献

1
Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study.卡那单抗治疗对秋水仙碱耐药的家族性地中海热儿童：一项为期6个月的开放标签、单臂试验研究。
Arthritis Rheumatol. 2014 Nov;66(11):3241-3. doi: 10.1002/art.38777.
2
Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies.白细胞介素-1β抑制剂卡那单抗在2型糖尿病患者中的安全性和耐受性：三项随机双盲研究的汇总分析
Cardiovasc Diabetol. 2014 May 17;13:94. doi: 10.1186/1475-2840-13-94.
3
Adding canakinumab to the Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for systemic juvenile idiopathic arthritis: Comment on the article by DeWitt et al.
将卡那单抗添加到儿童关节炎和风湿病研究联盟针对全身型幼年特发性关节炎的共识治疗方案中：对德维特等人文章的评论
Arthritis Care Res (Hoboken). 2014 Sep;66(9):1430-1. doi: 10.1002/acr.22343.
4
Treatment of acute gout: a systematic review.急性痛风的治疗：一项系统评价。
Semin Arthritis Rheum. 2014 Aug;44(1):31-8. doi: 10.1016/j.semarthrit.2014.02.003. Epub 2014 Feb 13.
5
Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series.卡那单抗抑制白细胞介素-1作为治疗难治性白塞病的一种成功单药策略：病例系列
Dermatology. 2014;228(3):211-4. doi: 10.1159/000358125. Epub 2014 Mar 12.
6
Successful treatment of refractory adult-onset still disease with canakinumab: a case report.卡那单抗成功治疗难治性成人起病型斯蒂尔病：一例报告
J Clin Rheumatol. 2014 Mar;20(2):121. doi: 10.1097/RHU.0000000000000082.
7
Pyoderma gangrenosum and concomitant hidradenitis suppurativa--rapid response to canakinumab (anti-IL-1β).坏疽性脓皮病合并化脓性汗腺炎——对卡那单抗（抗IL-1β）快速反应
Eur J Dermatol. 2013 May-Jun;23(3):408-10. doi: 10.1684/ejd.2013.2018.
8
Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study.
J Allergy Clin Immunol. 2013 Sep;132(3):751-754.e5. doi: 10.1016/j.jaci.2013.04.008. Epub 2013 May 24.
9
A case of hyperimmunoglobulinemia d syndrome successfully treated with canakinumab.1例用卡那单抗成功治疗的免疫球蛋白D血症综合征病例。
Case Rep Rheumatol. 2013;2013:795027. doi: 10.1155/2013/795027. Epub 2013 Apr 16.
10
Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment.鉴定出一名 PAPA 样综合征患者存在 PSTPIP1 基因纯合突变，该患者对康那奴单抗治疗有反应。
JAMA Dermatol. 2013 Feb;149(2):209-15. doi: 10.1001/2013.jamadermatol.717.